<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Early clinical outcomes as a function of use of newer oral P2Y 12 inhibitors versus clopidogrel in the EUROMAX trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-11-28">28 November 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Gregory</forename><surname>Ducrocq</surname></persName>
							<email>gregory.ducrocq@aphp.fr</email>
							<affiliation key="aff1">
								<orgName type="department">DHU FIRE</orgName>
								<orgName type="laboratory">FACT (French Alliance for Cardiovascular Trials) an F-CRIN network</orgName>
								<orgName type="institution">Hôpital Bichat</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Université Paris-Diderot</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">INSERM U-1148</orgName>
								<orgName type="institution" key="instit2">LVTS</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kurt</forename><surname>Huber</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">3rd Department of Medicine, Cardiology and Intensive Care Medicine</orgName>
								<orgName type="institution">Wilhelminen Hospital</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><forename type="middle">W</forename><surname>Hamm</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Kerckhoff Clinic and Thoraxcenter</orgName>
								<address>
									<settlement>Bad Nauheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arnoud</forename><surname>Van 't Hof</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Isala Klinieken</orgName>
								<address>
									<settlement>Zwolle</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frédéric</forename><surname>Lapostolle</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Cardiology Department</orgName>
								<orgName type="institution">Hôpitaux Universitaires, Paris-Seine Saint-Denis</orgName>
								<address>
									<settlement>Saint Denis</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pierre</forename><surname>Coste</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">Hôpital Cardiologique-Centre Hospitalier Universitaire Bordeaux</orgName>
								<orgName type="institution" key="instit2">Université de Bordeaux</orgName>
								<address>
									<settlement>Pessac</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Giovanni</forename><surname>Gordini</surname></persName>
							<affiliation key="aff8">
								<orgName type="laboratory">Intensive Care Unit and EMS</orgName>
								<orgName type="institution">Maggiore Hospital</orgName>
								<address>
									<settlement>Bologna</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacob</forename><surname>Steinmetz</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Emergency Medical Service of the Capital Region and Rigshospitalet</orgName>
								<orgName type="institution">Copenhagen University Hospital</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Freek</forename><forename type="middle">W A</forename><surname>Verheugt</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Onze Lieve Vrouwe Gasthuis (OLVG)</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jennifer</forename><surname>Adgey</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Royal Victoria Hospital</orgName>
								<address>
									<settlement>Belfast</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lutz</forename><surname>Nibbe</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Nephrology and Medical Intensive Care</orgName>
								<orgName type="institution">Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vojko</forename><surname>Kaniĉ</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">University Medical Centre Maribor</orgName>
								<address>
									<settlement>Maribor</settlement>
									<country key="SI">Slovenia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Clemmensen</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Department of Cardiology</orgName>
								<orgName type="department" key="dep2">Institute for Clinical Medicine</orgName>
								<orgName type="institution">University of Copenhagen</orgName>
								<address>
									<settlement>Rigshospitalet, Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="department">Department of General and Interventional Cardiology</orgName>
								<orgName type="institution">University Heart Center-Hamburg-Eppendorf</orgName>
								<address>
									<settlement>Hamberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Nykoebing F Hospital</orgName>
								<orgName type="institution">University of Southern Denmark</orgName>
								<address>
									<settlement>Odense</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uwe</forename><surname>Zeymer</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">Klinikum Ludwigshafen</orgName>
								<address>
									<settlement>Ludwigshafen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Debra</forename><surname>Bernstein</surname></persName>
							<affiliation key="aff18">
								<orgName type="institution">The Medicines Company</orgName>
								<address>
									<settlement>Parsippany</settlement>
									<region>New Jersey</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jayne</forename><surname>Prats</surname></persName>
							<affiliation key="aff18">
								<orgName type="institution">The Medicines Company</orgName>
								<address>
									<settlement>Parsippany</settlement>
									<region>New Jersey</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Efthymios</forename><forename type="middle">N</forename><surname>Deliargyris</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Science and Strategy Consulting Group</orgName>
								<address>
									<settlement>Basking Ridge</settlement>
									<region>New Jersey</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ph</forename><forename type="middle">Gabriel</forename><surname>Steg</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">DHU FIRE</orgName>
								<orgName type="laboratory">FACT (French Alliance for Cardiovascular Trials) an F-CRIN network</orgName>
								<orgName type="institution">Hôpital Bichat</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Université Paris-Diderot</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">INSERM U-1148</orgName>
								<orgName type="institution" key="instit2">LVTS</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="institution" key="instit1">National Heart and Lung Institute</orgName>
								<orgName type="institution" key="instit2">Imperial College</orgName>
								<orgName type="institution" key="instit3">ICMS</orgName>
								<orgName type="institution" key="instit4">Royal Brompton Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Early clinical outcomes as a function of use of newer oral P2Y 12 inhibitors versus clopidogrel in the EUROMAX trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-11-28">28 November 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">382D58CE029EAF78B7B0D5BB87D9F647</idno>
					<idno type="DOI">10.1136/openhrt-2017-000677</idno>
					<note type="submission">Received 13 June 2017 Revised 16 August 2017 Accepted 12 September 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:39+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>How might this impact on clinical practice?</head><p><s>► Optimal antithrombotic strategies need to be developed to improve short-term outcome in patients with STEMI.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objective To ascertain whether different oral P2Y 12 inhibitors might affect rates of acute stent thrombosis and 30-day outcomes after primary percutaneous coronary intervention (pPCI).</s><s>Methods The European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) randomised trial compared prehospital bivalirudin with heparin with optional glycoprotein IIb/IIIa inhibitor treatment in patients with ST-segment elevation myocardial infarction triaged to pPCI.</s><s>Choice of P2Y 12 inhibitor was at the investigator's discretion.</s><s>In a prespecified analysis, we compared event rates with clopidogrel and newer oral P2Y 12 inhibitors (prasugrel, ticagrelor).</s><s>Rates of the primary outcome (acute stent thrombosis) were examined as a function of the P2Y 12 inhibitor used for loading and 30-day outcomes (including major adverse cardiac events) as a function of the P2Y 12 inhibitor used for maintenance therapy.</s><s>Logistic regression was used to adjust for differences in baseline characteristics.</s></p><p><s>Results Prasugrel or ticagrelor was given as the loading P2Y 12 inhibitor in 49% of 2198 patients and as a maintenance therapy in 59%.</s><s>No differences were observed in rates of acute stent thrombosis for clopidogrel versus newer P2Y 12 inhibitors (adjusted OR 0.50, 95% CI 0.13 to 1.85).</s><s>After adjustment, no difference was observed in 30-day outcomes according to maintenance therapy except for protocol major (p=0.029) or minor (p=0.025)</s><s>bleeding and Thrombolysis In Myocardial Infarction minor bleeding (p=0.002), which were less frequent in patients on clopidogrel.</s><s>Consistent results were observed in the bivalirudin and heparin arms.</s><s>Conclusions The choice of prasugrel or ticagrelor over clopidogrel was not associated with differences in acute stent thrombosis or 30-day ischaemic outcomes after pPCI.</s><s>Trial registration number NCT01087723.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>InTROduCTIOn</head><p><s>A rapid and powerful platelet inhibition appears key in patients with ST-segment elevation myocardial infarction (STEMI) referred for primary percutaneous coronary intervention (pPCI).</s><s>In pivotal trials, 1 2 the use of prasugrel or ticagrelor versus clopidogrel was associated with a reduction in the rate of ischaemic events.</s><s>While the overall rate of stent thrombosis was reduced with prasugrel or ticagrelor in the overall population 1 2 as well as in the subgroup of patients with STEMI treated with pPCI, <ref type="bibr">3 4</ref> there was no difference in rates of acute stent thrombosis. <ref type="bibr">5 6</ref></s><s><ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref> The European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) trial <ref type="bibr" target="#b11">11</ref> compared prehospital bivalirudin with heparin (unfractionated heparin [UFH] or low-molecular-weight heparin) with/without glycoprotein IIb/IIIa inhibitor treatment and found a significant reduction in death or major bleeding with bivalirudin.</s><s>EUROMAX</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key questions</head><p><s>What is already known about this subject?</s></p><p><s>► Large randomised studies have associated prasugrel and ticagrelor with a reduction in ischaemic events versus clopidogrel in patients with acute coronary syndrome at long-term follow-up.</s></p><p><s>What does this study add?</s></p><p><s>► We found no significant differences in acute stent thrombosis between patients with ST-segment elevation myocardial infarction (STEMI) given prasugrel or ticagrelor versus clopidogrel.</s></p><p><s>also confirmed an observation from the HORIZONS-AMI trial <ref type="bibr" target="#b12">12</ref> of an increased risk of acute stent thrombosis of approximately 1% in absolute terms, which appeared confined to the 4 hours after the end of PCI. <ref type="bibr" target="#b13">13</ref> We aimed to investigate whether use of prasugrel or ticagrelor, versus clopidogrel, was associated with a reduction in the rate of acute stent thrombosis and whether either of the newer P2Y 12 inhibitors improved 30-day clinical outcomes, in the overall trial population and as a function of treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MeTHOds design and participants</head><p><s>The EUROMAX trial enrolled patients who presented within 12 hours of symptom onset with a presumed diagnosis of STEMI and undergoing pPCI ( ClinicalTrials.</s><s>gov registry, NCT01087723). <ref type="bibr" target="#b11">11</ref></s><s>The study complied with the Declaration of Helsinki.</s><s>The protocol was approved by local ethics committees and health authorities.</s><s>Patients provided written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatments</head><p><s>All patients received aspirin and an approved oral P2Y 12 inhibitor (clopidogrel, prasugrel, ticagrelor) as early as possible after first medical contact.</s><s>Decisions regarding the choice of P2Y 12 inhibitor, clopidogrel loading dose (300 or 600 mg) and other procedural options were left to physician preferences and local practices.</s><s>Patients were randomised to bivalirudin or UFH/low-molecular-weight heparin with or without a glycoprotein IIb/IIIa inhibitor (per investigator usual practice and guidelines).</s></p><p><s>Patients in the bivalirudin arm received a bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/ hour.</s><s>The protocol specified that the infusion could be continued for ≥4 hours after PCI at a dose of 0.25 mg/kg/ hour; however, continuation of the PCI dose (1.75 mg/ kg/hour) was permitted.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcomes</head><p><s>Patients were followed to 30 days.</s><s>The primary end point of this analysis was the occurrence of acute stent thrombosis as a function of the P2Y 12 inhibitor used for the loading dose (ie, ticagrelor or prasugrel vs clopidogrel).</s><s>Acute stent thrombosis was defined according to the Academic Research Consortium (ARC) definition as a stent thrombosis occurring &lt;24 hours after the index PCI. <ref type="bibr" target="#b14">14</ref></s><s>Multiple secondary outcomes were analysed at 30 days, all of which were end points of the EUROMAX trial. <ref type="bibr" target="#b11">11</ref></s><s>n the EUROMAX trial, the primary outcome was the composite of all-cause death or protocol major bleeding not related to coronary artery bypass graft (CABG) surgery at 30 days.</s><s>The key secondary 30-day outcome was a composite of all-cause death, myocardial re-infarction or non-CABG major bleeding.</s><s>Other prespecified secondary outcomes included major adverse cardiovascular events (MACE; a composite of death, re-infarction, ischaemia-driven revascularisation or stroke), net adverse clinical events (NACE, a composite of MACE and non-CABG major bleeding), each of the components of the primary and principle secondary outcomes, ischaemia-driven revascularisation, major and minor bleeding, and ARC-defined stent thrombosis. <ref type="bibr" target="#b14">14</ref></s><s>rotocol-defined major bleeding was defined as bleeding unrelated to CABG surgery that included intracranial, retroperitoneal or intraocular bleeding; accesssite haemorrhage requiring radiological or surgical intervention; a reduction in the haemoglobin concentration of &gt;4 g/dL (2.5 mmol/L) without an overt source of bleeding; a reduction in the haemoglobin concentration of 3 g/dL (1.8 mmol/L) with an overt source of bleeding; re-intervention for bleeding; or use of any blood-product transfusion.</s><s>Access-site haematomas, which did not require surgical or radiological intervention, were not counted as major bleeds regardless of their size.</s><s>Protocol minor bleeding was defined as all other non-CABG-related bleeding or transfusion events.</s><s>Bleeding events were also classified according to the Thrombolysis In Myocardial Infarction (TIMI) criteria. <ref type="bibr" target="#b15">15</ref></s><s>atistical analysis A prespecified comparison of outcomes as a function of oral P2Y 12 inhibitor used (prasugrel or ticagrelor vs clopidogrel) was performed.</s><s>Analyses were performed in the intent-to-treat population.</s><s>The χ 2 test or Fisher's exact test was used for comparisons of event rates.</s><s>The log-rank test was used to compute the significance of time-toevent data.</s><s>Continuous variables are reported as medians (IQRs).</s><s>The Wilcoxon rank-sum test was used to compare continuous variables.</s><s>A p value of &lt;0.05 was considered significant.</s><s>Categorical variables are reported as frequencies and percentages.</s><s>Rates of acute stent thrombosis were examined as a function of the P2Y 12 inhibitor used for loading, and 30-day outcomes were examined as a function of the P2Y 12 inhibitor used for maintenance therapy.</s><s>To account for differences in baseline characteristics in this postrandomisation subgroup analysis, a logistic regression analysis was performed.</s><s>Variables in the logistic regression model included age &gt;65 years, female sex, anaemia, hypertension, hyperlipidaemia, diabetes, smoking, creatinine clearance ≤60 mL/min, prasugrel/ ticagrelor versus clopidogrel, history of myocardial infarction, previous CABG, previous PCI, Killip class ≥II, access site (femoral vs radial), pre-PCI TIMI flow 0 or 1, single-vessel disease, placement of a drug-eluting stent, and treatment with bivalirudin versus standard of care.</s><s>Analyses were performed with the use of SAS software, V.9.2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ResulTs</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Population</head><p><s>Of the 2198 patients triaged to pPCI in the EUROMAX trial, 2104 (95.7%) received an oral P2Y 12 inhibitor loading dose (90.9% received the loading dose before angiography).</s><s>Clopidogrel was used for loading in 1069 patients, prasugrel in 629 patients and ticagrelor in 406 Interventional cardiology patients.</s><s>P2Y 12 inhibitor maintenance therapy after the procedure was used in 1927 patients (87.7%).</s><s>Eight of these received ticlopidine and were excluded, leaving a population of 1919 patients.</s><s>Figure <ref type="figure" target="#fig_0">1</ref> details the numbers of patients with data who received loading and maintenance doses for each drug.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Baseline characteristics</head><p><s>Patient and procedural characteristics according to P2Y 12 inhibitor loading are shown in table 1. Patients given clopidogrel for the loading dose were older, more likely to be female, to have a history of myocardial infarction and to have had a failed procedure.</s><s>In contrast, they were less likely to present with congestive heart failure and to have the procedure done by the radial approach.</s><s>The type of P2Y 12 inhibitor used for the loading dose was highly dependent on the country in which the patient was randomised.</s><s>Patients who had a clopidogrel loading dose were more likely than those on prasugrel or ticagrelor to receive it before the angiogram was performed.</s><s>Median delays between loading dose and angiogram were 50 min (IQR 35 to 66) in the overall population, 48 min (IQR 30 to 65) in patients who received newer P2Y 12 inhibitors as loading dose and 51 min (IQR 38 to 67) in patients who received clopidogrel as loading dose.</s></p><p><s>Patients on clopidogrel maintenance therapy showed features indicative of higher cardiovascular risk, with an older age, higher prevalence of major risk factors and history of myocardial infarction, higher Killip class and kidney dysfunction (see supplementary table <ref type="table" target="#tab_0">S1</ref>).</s><s>In addition, the rate of pre-PCI TIMI 3 flow was lower for patients receiving clopidogrel; they also had PCI less frequently performed and more frequently had a procedural failure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acute stent thrombosis according to loading P2Y 12 inhibitor</head><p><s>The rate of acute stent thrombosis did not differ according to the P2Y 12 used for the loading dose: eight patients (0.8%) with prasugrel or ticagrelor versus five patients (0.5%) with clopidogrel (p=0.37).</s><s>One additional case of stent thrombosis was excluded from the analysis due to missing data on the loading dose.</s><s>After adjustment, no difference was observed (adjusted OR 0.50, 95% CI 0.13 to 1.85, p=0.30, figure <ref type="figure" target="#fig_1">2</ref>).</s></p><p><s>Thirty-day outcomes according to P2Y 12 used for maintenance dose There was no association between the type of P2Y 12 inhibitor used for the maintenance dose and rates of the 30-day endpoints (table 2).</s><s>The rate of death was lower (1.3% vs 2.7%; p=0.03), and minor bleeds were higher in patients on prasugrel or ticagrelor (table <ref type="table" target="#tab_1">2</ref>).</s><s>The rate of stent thrombosis was similar across subsets defined according to type of P2Y 12 inhibitor.</s></p><p><s>After adjustment, there was no significant difference in clinical outcomes between groups except for lower rates of protocol major bleeding (p=0.029) and minor bleeding (p=0.025), as well as TIMI minor bleeding (p=0.0002) with clopidogrel (figure <ref type="figure" target="#fig_1">2</ref>).</s><s>effect of P2Y 12 type according to treatment arm (bivalirudin vs heparin with optional glycoprotein IIb/IIIa) Information on the loading and maintenance P2Y 12 inhibitors used in the bivalirudin and heparin (with optional glycoprotein IIb/IIIa inhibitor) treatment arms is detailed in supplementary table <ref type="table" target="#tab_1">S2</ref>.</s></p><p><s>Overall, the benefits of bivalirudin over heparin with optional glycoprotein IIb/IIIa inhibitor treatment were consistent across subgroups defined by the use of prasugrel/ticagrelor or clopidogrel, with no statistical interaction between these subgroups (table <ref type="table" target="#tab_1">2</ref>).</s><s>In particular, the interaction for acute stent thrombosis according to loading dose was not significant (p=0.74).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>dIsCussIOn</head><p><s>In this prespecified analysis from the EUROMAX trial, we observed that use of the newer oral P2Y 12 inhibitors, prasugrel or ticagrelor, was not associated with a lower rate of acute stent thrombosis or 30-day ischaemic outcomes as compared with the use of clopidogrel.</s></p><p><s>Rapid and potent platelet inhibition is key in order to reduce the risk of ischaemic complications in patients with STEMI.</s><s>As a consequence, current guidelines recommend the early use of P2Y 12 inhibitors. <ref type="bibr">16 17</ref></s><s>However, whereas the European Society of Cardiology guidelines <ref type="bibr" target="#b16">16</ref> recommend using prasugrel or ticagrelor over clopidogrel, the American College of Cardiology/American Heart Association guidelines <ref type="bibr" target="#b17">17</ref> stipulate the same level of recommendation for all three.</s></p><p><s>The absence of a difference in the rate of acute stent thrombosis according to the oral P2Y 12 inhibitor used for the loading dose in our analysis is consistent with the existing literature.</s><s>In the PLATO trial, the rate of acute stent thrombosis was not significantly different in patients on ticagrelor versus those on clopidogrel. <ref type="bibr" target="#b5">5</ref></s><s>In the ATLANTIC trial, prehospital administration of ticagrelor did not improve pre-PCI coronary reperfusion.</s><s>]<ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref> This delay may be due to several factors, including the action of morphine or morphine derivatives, which are frequently used prehospital or intrahospital to relieve pain in patients with STEMI <ref type="bibr">10 18 19</ref> and haemodynamic dysfunction in patients with shock or preshock. <ref type="bibr" target="#b20">20</ref></s><s> The lack of a difference in 30-day outcomes according to the P2Y 12 inhibitor used as maintenance treatment in our study appears somewhat at variance with the results of the TRITON and PLATO trials, both of which demonstrated a significant reduction in the rate of ischaemic events in the overall population as well as in the group with STEMI. 1 2 However, the present analysis is underpowered since EUROMAX was much a smaller trial than TRITON or PLATO, and we analysed 30 day rather than 1-year outcomes.</s></p><p><s>As detailed in figure <ref type="figure" target="#fig_0">1</ref>, a substantial proportion of patients had a switch of P2Y 12 inhibitor between loading and maintenance doses.</s><s>This is probably because the loading dose was administered in a prehospital setting for most patients, while the maintenance dose was given in hospital.</s><s>Hospital and prehospital antiplatelet protocols might differ as they are usually managed by different teams.</s><s>This might be a confounding factor when analysing 30-day outcomes.</s></p><p><s>The use of bivalirudin for pPCI has been associated with an increase in the risk of acute stent thrombosis. <ref type="bibr">11 12</ref></s><s>In the HEAT-PPCI trial, despite the fact that newer oral P2Y 12 inhibitors were used in &gt;90% of cases, an increase in both early stent thrombosis and other ischaemic events was observed. <ref type="bibr" target="#b21">21</ref></s><s>Those results are consistent with our observations.</s><s>The mechanism of bivalirudin-associated acute stent thrombosis is probably associated with a rapid clearance of the drug after discontinuation of the drug, resulting in an insufficient thrombin inhibition in the first hours following stent implantation and prior to the effectiveness of oral antiplatelet agents.</s><s>Therefore, there is a 'gap' in antithrombotic protection. <ref type="bibr">8 9 22</ref></s><s>4]<ref type="bibr" target="#b25">[25]</ref> In contrast, several analyses tend to demonstrate that potent post-PCI thrombin inhibition decreases the risk of acute stent thrombosis.</s><s>In the BRIGHT trial, <ref type="bibr" target="#b28">26</ref> in a subgroup analysis from EUROMAX <ref type="bibr" target="#b29">27</ref> and in an exploratory analysis of the MATRIX trial, <ref type="bibr" target="#b30">28</ref> patients who received a prolonged infusion of bivalirudin at the full dose of 1.75 mg/kg/hour after PCI had no excess risk of acute stent thrombosis.</s><s>limitations These data were derived from a prespecified analysis of postrandomisation data.</s><s>Thus, the decision to use clopidogrel or one of the newer P2Y 12 inhibitors was left to the discretion of the investigators and confounding cannot be excluded.</s><s>In addition, there were major differences in the geographical distribution and the baseline clinical characteristics as a function of the agent used, some of which can affect the risk of ischaemic or bleeding complications.</s><s>Even if we performed multivariable adjustments, our results may be partially due to residual confounding.</s><s>The low number of events and the large CI observed in the comparison of stent thrombosis between the two groups makes a statistical type 2 error possible.</s><s>This result should therefore be interpreted with caution.</s><s>The fact that most patients received pretreatment with P2Y 12 inhibitors might have attenuated differences in platelet inhibition between the two groups.</s><s>However, precise information on the timing of the administration of the loading dose is not available.</s><s>The relatively low numbers of patients receiving each of the two newer P2Y 12 agents and low number of stent thromboses prevent a sound comparison between prasugrel and ticagrelor.</s><s>This comparison is currently being done in a randomised trial (ISAR-REACT 5 trial NCT01944800).</s><s>Finally, EUROMAX was an open-label trial.</s><s>However, a central adjudication committee blinded to treatment allocation reviewed all events.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>COnClusIOns</head><p><s>The rate of acute stent thrombosis did not differ between patients who received a loading dose of prasugrel or ticagrelor and those who received clopidogrel.</s><s>Following adjustment, 30-day outcomes were similar between patients receiving prasugrel or ticagrelor and those receiving clopidogrel for the maintenance dose, with the exception of an increased risk of bleeding events with the newer agents.</s><s>These results were consistent regardless of the anticoagulation strategy used.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Flow chart.</s><s>The numerical differences between loading and maintenance dose totals are due to missing data.</s></p></div></figDesc><graphic coords="3,44.42,49.50,240.96,120.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Adjusted* ORs for outcomes by maintenance P2Y 12 treatment.</s><s>*Adjusted for age&gt;65 years, anaemia, bivalirudin versus heparin±glycoprotein IIb/IIIa inhibitor, new P2Y 12 maintenance dose, creatinine clearance ≤60 vs &gt;60 mL/min, current smoker, diabetes, drug-eluting stent, female sex, femoral versus radial access, hyperlipidaemia, hypertension, Killip class≥II, preprocedural TIMI flow 0/1 vs 2/3, history of coronary artery bypass graft, previous percutaneous coronary intervention, previous MI, single-vessel disease.</s><s>MACE, major adverse cardiac events (death or myocardial infarction, ischaemia-driven revascularisation or stroke); MI, myocardial infarction; NACE, net adverse clinical events (death or myocardial infarction, ischaemia-driven revascularisation, stroke or bleeding); TIMI, Thrombolysis In Myocardial Infarction.</s></p></div></figDesc><graphic coords="5,113.34,49.50,368.40,184.32" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Patient and procedural characteristics according to loading P2Y12 inhibitor</s></p></div></figDesc><table><row><cell>Characteristics</cell><cell>Prasugrel or ticagrelor, n=1035</cell><cell>Clopidogrel, n=1069</cell><cell>p Value</cell></row><row><cell>Age, years</cell><cell>60.0±12.1</cell><cell>63.1±13.3</cell><cell>&lt;0.0001</cell></row><row><cell>Women</cell><cell>222 (21.4)</cell><cell>272 (25.4)</cell><cell>0.031</cell></row><row><cell>Diabetes</cell><cell>142 (13.7)</cell><cell>136 (12.7)</cell><cell>0.50</cell></row><row><cell>Current smoker (within past 30 days)</cell><cell>439 (42.5)</cell><cell>466 (43.6)</cell><cell>0.009</cell></row><row><cell>Hypertension</cell><cell>434 (42.0)</cell><cell>470 (44.0)</cell><cell>0.36</cell></row><row><cell>Previous myocardial infarction</cell><cell>75 (7.3)</cell><cell>105 (9.8)</cell><cell>0.035</cell></row><row><cell>Previous PTCA/PCI</cell><cell>87 (8.4)</cell><cell>102 (9.5)</cell><cell>0.37</cell></row><row><cell>Previous CABG</cell><cell>18 (1.7)</cell><cell>26 (2.4)</cell><cell>0.27</cell></row><row><cell>Hyperlipidaemia*</cell><cell>424 (41.0)</cell><cell>337 (31.5)</cell><cell>&lt;0.0001</cell></row><row><cell>Country</cell><cell></cell><cell></cell><cell>&lt;0.0001</cell></row><row><cell>France</cell><cell>554 (53.5)</cell><cell>233 (21.8)</cell><cell></cell></row><row><cell>Netherlands</cell><cell>251 (24.3)</cell><cell>507 (47.4)</cell><cell></cell></row><row><cell>Germany</cell><cell>120 (11.6)</cell><cell>93 (8.7)</cell><cell></cell></row><row><cell>Denmark</cell><cell>85 (8.2)</cell><cell>61 (5.7)</cell><cell></cell></row><row><cell>Other †</cell><cell>25 (2.4)</cell><cell>175 (16.4)</cell><cell></cell></row><row><cell>Killip class</cell><cell></cell><cell></cell><cell>0.11</cell></row><row><cell>I</cell><cell>851/921 (92.4)</cell><cell>929/986 (94.2)</cell><cell></cell></row><row><cell>II to IV</cell><cell>70/921 (7.6)</cell><cell>57/986 (5.8)</cell><cell></cell></row><row><cell>Creatinine clearance</cell><cell></cell><cell></cell><cell>&lt;0.0001</cell></row><row><cell>≤60 mL/min</cell><cell>123/924 (13.3)</cell><cell>168/991 (17.0)</cell><cell></cell></row><row><cell>&gt;60 mL/min</cell><cell>801/924 (86.7)</cell><cell>823/991 (83.0)</cell><cell></cell></row><row><cell>Anaemia</cell><cell>106/918 (11.5)</cell><cell>151/971 (15.6)</cell><cell>0.011</cell></row><row><cell>P2Y 12 loading dose before angiography</cell><cell>882/1012 (87.2)</cell><cell>953/1007 (94.6)</cell><cell>&lt;0.0001</cell></row><row><cell>Pre-PCI TIMI 3 flow</cell><cell>207/923 (22.4)</cell><cell>178/899 (19.8)</cell><cell>0.020</cell></row><row><cell>PCI performed</cell><cell>928/1035 (89.7)</cell><cell>918/1069 (85.9)</cell><cell>0.0081</cell></row><row><cell>Radial access</cell><cell>608/1027 (59.2)</cell><cell>396/1037 (38.2)</cell><cell>&lt;0.0001</cell></row><row><cell>Thrombectomy</cell><cell>308/928 (33.2)</cell><cell>291/918 (31.7)</cell><cell>0.49</cell></row><row><cell>Post-PCI TIMI 3 flow</cell><cell>884/923 (95.8)</cell><cell>844/898 (94.0)</cell><cell>0.35</cell></row><row><cell>Procedural complication</cell><cell>57/928 (6.1)</cell><cell>66/918 (7.2)</cell><cell>0.37</cell></row><row><cell>Failed procedure</cell><cell>10/928 (1.1)</cell><cell>24/918 (2.6)</cell><cell>0.014</cell></row><row><cell>Anticoagulant used</cell><cell></cell><cell></cell><cell>0.043</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Unadjusted outcomes by P2Y12 inhibitor Interaction p value for the interaction between choice of P2Y 12 inhibitor and effect of bivalirudin versus heparin.</s><s>†According to P2Y 12 loading dose.</s><s>‡p Value calculated using Fisher's exact test.</s><s>All other p values calculated using the χ 2 test.</s><s>§According to P2Y 12 maintenance dose.</s><s>MACE, major adverse cardiovascular events (death, reinfarction, ischaemia-driven revascularisation or stroke); NACE, net adverse clinical events (death, reinfarction, ischaemia-driven revascularisation, stroke or major bleeding); TIMI, Thrombolysis In Myocardial Infarction.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Interaction</cell><cell></cell></row><row><cell>Outcome</cell><cell cols="2">Prasugrel or ticagrelor n=1135 Clopidogrel n=784</cell><cell>p Value</cell><cell>p Value*</cell><cell></cell></row><row><cell>Acute stent thrombosis (≤24 hour) †</cell><cell>8/1035 (0.8)</cell><cell>5/1069 (0.5)</cell><cell>0.37 ‡</cell><cell>0.74</cell><cell></cell></row><row><cell>30-day outcomes §</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Death or major bleeding</cell><cell>63 (5.6)</cell><cell>47 (6.0)</cell><cell>0.68</cell><cell>0.47</cell><cell></cell></row><row><cell>Death, reinfarction or major bleeding Death Cardiac death Protocol bleeding Major Minor Major or minor</cell><cell>77 (6.8) 15 (1.3) 14 (1.2) 53 (4.7) 88 (7.8) 141 (12.4)</cell><cell>56 (7.1) 21 (2.7) 18 (2.3) 30 (3.8) 43 (5.5) 73 (9.3)</cell><cell>0.76 0.03 0.07 0.37 0.05 0.03</cell><cell>0.74 0.69 0.87 0.90 0.93 0.88</cell><cell>http://openheart.bmj.com/</cell></row><row><cell>TIMI bleeding Major Minor Reinfarction Stent thrombosis (definite) Subacute (&gt;24 hours to 30 days) MACE § NACE § Data are presented as n (%) or n/N (%).</cell><cell>19 (1.7) 122 (10.7) 15 (1.3) 13 (1.1) 4 (0.4) 44 (3.9) 90 (7.9)</cell><cell>15 (1.9) 56 (7.1) 11 (1.4) 8 (1.0) 5 (0.6) 43 (5.5) 66 (8.4)</cell><cell>0.70 0.007 0.88 0.80 0.50 ‡ 0.10 0.70</cell><cell>0.97 0.93 0.39 0.11 0.33 0.86 0.82</cell><cell>on May 17, 2022 by guest. Protected by copyright.</cell></row></table><note><p><s>*</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">on May 17, 2022 by guest. Protected by copyright. http://openheart.bmj.com/ Open Heart: first published as 10.1136/openhrt-2017-000677 on 28 November 2017. Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Open Heart: first published as 10.1136/openhrt-2017-000677 on 28 November 2017. Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Huber K, et al. Open Heart 2017;4:e000677. doi:10.1136/openhrt-2017-000677</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" />
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Interventional cardiology</head><p><s>Contributors Conceived and designed the research: KH, GD, PGS.</s><s>Performed statistical analysis: DB, JP.</s><s>Handled funding and supervision: PGS, KH, GD, END.</s><s>Acquired the data: KH, GD, CWH, AVH, FL, PCl, GG, JS, FWV, JA, LN, VK, PCo, UZ.</s><s>Drafted the manuscript: GD, KH, PGS.</s><s>Made critical revision of the manuscript for key intellectual content: all authors.</s></p><p><s>Funding This work was supported by The Medicines Company, Parsippany, New Jersey, USA.</s></p><p><s>Competing interests KH has received personal fees from Daiichi Sankyo, Eli Lilly and The Medicines Company and personal fees and grants from AstraZeneca.</s><s>GD has received personal fees from AstraZeneca, Biotronik, Bristol-Myers Squibb, Daiichi Sankyo and Eli Lilly.</s><s>CWH has received personal fees from AstraZeneca, Eli Lilly and Sanofi-Aventis.</s><s>AH has received grants from Daiichi Sankyo, Iroko and Medtronic.</s><s>FL has received personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Correvio, Eli Lilly, Merck-Serono and The Medicines Company.</s><s>PCo has received personal fees from The Medicines Company and grants from Daiichi Sankyo.</s><s>GG has no disclosure to report.</s><s>JS has received personal fees and grants from The Medicines Company.</s><s>FWAV has received personal fees from AstraZeneca, Boehringer Ingelheim and Eli Lilly.</s><s>JA has no disclosures to report.</s><s>LN has received personal fees from Boehringer Ingelheim Pharma GmbH&amp;Co.</s><s>KG and The Medicines Company.</s><s>VK has received personal fees from AstraZeneca and Boston Scientific.</s><s>PCl has received personal fees from Bayer, Boehringer Ingelheim and Bristol-Myers Squibb and personal fees and grants from AstraZeneca, Daiichi Sanko, Eli Lilly, Medtronic, Pfizer, Sanofi and The Medicines Company.</s><s>UZ has received personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharpe &amp; Dohme, Novartis, Pfizer and Sanofi.</s><s>DB has received personal fees from The Medicines Company.</s><s>JP has received personal fees from The Medicines Company.</s><s>END was an employee of The Medicines Company at the time of the analysis and remains a shareholder.</s><s>PGS has received personal fees from Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Janssen, Medtronic, Merck Sharpe &amp; Dohme, Novartis, Pfizer, Regeneron and Roche, personal fees and grants from Sanofi and Servier, and personal fees and non-financial support from The Medicines Company.</s></p><p><s>Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity.</s><s>The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ethics approval Local ethics committees and health authorities.</head><p><s>Provenance and peer review Not commissioned; externally peer reviewed.</s></p><p><s>Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</s><s>See: http:// creativecommons.</s><s>org/ licenses/ by-nc/ 4. 0/</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; TIMI, Thrombolysis In Myocardial Infarction</title>
		<imprint>
			<date type="published" when="2022-05-17">May 17. 2022</date>
			<pubPlace>Czech Republic, Italy, Poland, Slovenia</pubPlace>
		</imprint>
	</monogr>
	<note>by guest. Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prasugrel versus clopidogrel in patients with acute coronary syndromes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Wiviott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braunwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Mccabe</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa0706482</idno>
		<ptr target="http://openheart.bmj.com/OpenHeart:firstpublishedas10.1136/openhrt-2017-000677on28" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="page" from="2001" to="2015" />
			<date type="published" when="2007">November 2017. 2007</date>
		</imprint>
	</monogr>
	<note>Downloaded from RefeRences 1</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Ticagrelor versus clopidogrel in patients with acute coronary syndromes</title>
		<author>
			<persName><forename type="first">L</forename><surname>Wallentin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Budaj</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa0904327</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="page" from="1045" to="1057" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial</title>
		<author>
			<persName><forename type="first">G</forename><surname>Montalescot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Wiviott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braunwald</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(09)60441-4</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="723" to="731" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Harrington</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCULATIONAHA.109.927582</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="2131" to="2141" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Emanuelsson</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCULATIONAHA.113.002589</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1055" to="1065" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Wiviott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braunwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Mccabe</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(08)60422-5</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="1353" to="1363" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Valgimigli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tebaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Campo</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcin.2012.01.006</idno>
	</analytic>
	<monogr>
		<title level="j">JACC Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="268" to="277" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Parodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Valenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bellandi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jacc.2013.01.024</idno>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="1601" to="1606" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction</title>
		<author>
			<persName><forename type="first">D</forename><surname>Alexopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Xanthopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gkizas</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCINTERVENTIONS.112.972323</idno>
	</analytic>
	<monogr>
		<title level="j">Circ Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="797" to="804" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention</title>
		<author>
			<persName><forename type="first">G</forename><surname>Parodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bellandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Xanthopoulou</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCINTERVENTIONS.114.001593</idno>
	</analytic>
	<monogr>
		<title level="j">Circ Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Bivalirudin started during emergency transport for primary PCI</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van 't Hof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Hamm</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1311096</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="2207" to="2217" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Bivalirudin during primary PCI in acute myocardial infarction</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Witzenbichler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Guagliumi</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa0708191</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="2218" to="2230" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Early stent thrombosis and mortality after primary percutaneous coronary intervention in stsegment-elevation myocardial infarction: A patient-level analysis of 2 randomized trials</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Dangas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Schoos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCINTERVENTIONS.115.003272</idno>
	</analytic>
	<monogr>
		<title level="j">Circ Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e003272</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Clinical end points in coronary stent trials: a case for standardized definitions</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Cutlip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Windecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mehran</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIRCULATIONAHA.106.685313</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="2344" to="2351" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pratt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berke</surname></persName>
		</author>
		<idno type="DOI">10.1016/0735-1097(88)90158-1</idno>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Atar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="2569" to="2619" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>O'gara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Kushner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Ascheim</surname></persName>
		</author>
		<idno type="DOI">10.1161/CIR.0b013e3182742c84</idno>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="529" to="555" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Prehospital ticagrelor in ST-segment elevation myocardial infarction</title>
		<author>
			<persName><forename type="first">G</forename><surname>Montalescot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Van 't Hof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lapostolle</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1407024</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="1016" to="1027" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Hobl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schoergenhofer</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00392-015-0927-z</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Res Cardiol</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="349" to="355" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction</title>
		<author>
			<persName><forename type="first">P</forename><surname>Osmancik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jirmar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hulikova</surname></persName>
		</author>
		<idno type="DOI">10.1002/ccd.22248</idno>
	</analytic>
	<monogr>
		<title level="j">Catheter Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="158" to="166" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Shahzad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kemp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mars</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(14)60924-7</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">384</biblScope>
			<biblScope unit="page" from="1849" to="1858" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap</title>
		<author>
			<persName><forename type="first">D</forename><surname>Alexopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Bhatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Hamm</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2015.04.012</idno>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page" from="3" to="12" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Effect of platelet inhibition with cangrelor during PCI on ischemic events</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Bhatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Mahaffey</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1300815</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="1303" to="1313" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Bhatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Gibson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcin.2014.09.025</idno>
	</analytic>
	<monogr>
		<title level="j">JACC Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="424" to="433" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Bhatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Hamm</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(13)61615-3</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="page" from="1981" to="1992" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>on May 17, 2022 by guest. Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<idno type="DOI">10.1136/openhrt-2017-000677on28</idno>
		<ptr target="http://openheart.bmj.com/OpenHeart" />
		<imprint>
			<date type="published" when="2017-11">November 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Huber</surname></persName>
		</author>
		<idno type="DOI">10.1136/openhrt-2017-000677</idno>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">e000677</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2015.2323</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="page" from="1336" to="1346" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Clemmensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wiberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van't Hof</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="214" to="220" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">BIvalirudin or unfractionated heparin in acute coronary syndromes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Valgimigli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Frigoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Leonardi</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1507854</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="997" to="1009" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title/>
		<idno type="DOI">10.1136/openhrt-2017-000677on28</idno>
		<ptr target="http://openheart.bmj.com/OpenHeart" />
		<imprint>
			<date type="published" when="2017-11">November 2017</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
